Edesa Biotech prices $25.0 million public offering at $5.50 per share
Edesa Biotech, Inc. priced an underwritten public offering of 3,870,500 common shares and pre-funded warrants for up to 675,000 common shares, each sold with a common share warrant, with gross proceeds expected to be approximately $25.0 million. The company expects net proceeds of approximately $23.1 million, to be used for general corporate purposes, and expects the offering to close on or about August 21, 2026, which adds new shares and warrants that can dilute existing shareholders.
Key points
- Combined offering price of $5.50 per common share with a warrant, and $5.4999 per pre-funded warrant with a warrant.
- Expected net proceeds of approximately $23.1 million; closing expected on or about August 21, 2026.
- Warrants have a $7.50 exercise price and expire on the earlier of the 18-month anniversary of issuance or 30 days after public announcement of Phase 2 vitiligo topline data for EB06.
- Underwriters hold a 30-day option to buy up to 681,825 additional shares; executive officers and directors agreed to a 90-day lock-up, subject to exceptions.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.